276 related articles for article (PubMed ID: 34344494)
1. ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism.
Bhatt MD; Portman MA; Berger F; Jacobs JP; Newburger J; Duggal A; Grosso M; Pandya G; Dave J; Goldenberg NA
Cardiol Young; 2021 Aug; 31(8):1213-1219. PubMed ID: 34344494
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.
Portman MA; Jacobs JP; Newburger JW; Berger F; Grosso MA; Duggal A; Tao B; Goldenberg NA;
J Am Coll Cardiol; 2022 Dec; 80(24):2301-2310. PubMed ID: 36328157
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
4. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M;
Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737
[TBL] [Abstract][Full Text] [Related]
6. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
8. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
9. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E; Galán AM
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):445-58. PubMed ID: 24471416
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
13. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
14. Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.
Payne RM; Burns KM; Glatz AC; Male C; Donti A; Brandão LR; Balling G; VanderPluym CJ; Bu'Lock F; Kochilas LK; Stiller B; Cnota JF; Rahkonen O; Khan A; Adorisio R; Stoica S; May L; Burns JC; Saraiva JFK; McHugh KE; Kim JS; Rubio A; Chía-Vazquez NG; Meador MR; Dyme JL; Reedy AM; Ajavon-Hartmann T; Jarugula P; Carlson-Taneja LE; Mills D; Wheaton O; Monagle P
J Am Coll Cardiol; 2023 Dec; 82(24):2296-2309. PubMed ID: 38057072
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
[TBL] [Abstract][Full Text] [Related]
18. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
[TBL] [Abstract][Full Text] [Related]
19. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
20. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]